China
-
GSK expands China footprint through Sino Biopharmaceutical partnership for Hepatitis B therapy bepirovirsen
CTTQ will also purchase a supply of bepirovirsen for an initial period of five and a half years, while GSK will record product sales from the arrangement, though the companies are not disclosing the financial value of the deal.
-
Bristol Myers Squibb bets US$15.2B on Hengrui partnership to accelerate global drug pipeline
Hengrui will oversee the initial human clinical studies for the immunology assets licensed from BMS, a move intended to speed up proof-of-concept data generation.
-
Biogen secures global rights to felzartamab in US850M deal with TJ Biopharma
Biogen now holds worldwide rights to the investigational therapy, felzartamab, which is currently undergoing Phase 3 clinical trials for several immune-mediated diseases.
-
Chinese CAR-T biotech Oricell Therapeutics raises USD110M in pre-IPO funding round
Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, and Qiming Venture Partners co-led the financing initiative.
-
Rwanda’s Masaka Hospital receives surgical equipment upgrade from China
The donation includes a hydraulic integrated operating table, a stainless steel instrument table, a manual wheelchair, and a surgical operating lamp.
-
Merck restructures China vaccine deal as Gardasil demand collapses
This shift applies to all three Merck vaccines distributed by Zhifei: Gardasil, the rotavirus vaccine RotaTeq, and the pneumococcal vaccine Pneumovax 23.
-
GSK’s Exdensur secures NMPA approval in China for chronic rhinosinusitis
The medication works as an add-on therapy alongside intranasal corticosteroids for patients whose condition fails to respond adequately to systemic corticosteroids or surgical intervention.
-
ImmunityBio secures first Asian approval for Anktiva bladder cancer drug in Macau
The drug targets a specific immune deficit associated with bladder cancer, offering a mechanism distinct from conventional treatments.
-
Novartis commits USD480M to scale China operations amid multinational investment surge
Novartis will direct the funds toward upgrading its manufacturing plant in Beijing and expanding its R&D campus in Shanghai, where it also houses its Chinese headquarters.
-
AstraZeneca invests in Shanghai’s cell therapy manufacturing hub
The new production hub will be located in the Lin-gang Special Area of the Shanghai Free Trade Zone, where it will supply autologous CAR-T therapies to China and other Asian markets.